Redeye updates its view on Genovis following the Q2 report and the announced divestment of its antib...
Redeye states that the Q2 report came in weaker than expected, with both sales and costs surprising ...
Redeye saw a Q2 report in which sales and gross margins did not deviate much from our expectations, ...
Redeye saw a report with sales that were in line with better-than-expected results.
Redeye updates its view on Flexion Mobile following its Q2 2024 report.
Redeye provides an update on Thunderful Group following its Q2 2024 report.
Zoomability Int AB (”Zoomability” eller ”bolaget”) publicerade den 21 augusti 2024 bolagets delårsra...
Redeye provides a preview for Integrum’s Q1 report, due on Thursday, August 29.
Q2 in line: sales up 11% y-o-y, adj. EBIT margin 37% (24%) Guides for -0.
Arctic Blue Beverages har publicerat bolagets delårsrapport för det andra kvartalet år 2024.
Redeye is encouraged to see AroCell recording its first quarter with a positive cash flow, and the r...
AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market.
Redeye is optimistic about today’s news from Egetis Therapeutics that patients on Emcitate are assoc...
Elanders har agerat offensivt med förvärv i den tidigare svackan.
Angler Gaming levererade en kv2 2024-rapport över vår förväntan avseende lönsamhet.
We initiate coverage of LapWall with a BUY-rating and TP of EUR 3.
Biosergen has together with Indian Alkem initiated patient studies with its drug candidate BSG005 fo...
Björn Borg (“Björn Borg”, “the Company” or “the Group”) is a well-established and renowned company w...
Ahead of Solwers' Q2 report on 30 August, we update our estimates to reflect two acquisitions conduc...
Redeye comments on Modelon's Q2 2024 report, which was in line with our expectations.
